Company Valuation: Northeast Pharmaceutical Group Co., Ltd.

Data adjusted to current consolidation scope
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Market Cap 1 6,848 8,384 9,051 7,646 7,531 7,449
Change - 22.43% 7.95% -15.52% -1.5% -1.09%
Enterprise Value (EV) 1 7,967 8,322 7,403 4,178 4,656 5,959
Change - 4.45% -11.04% -43.57% 11.44% 27.99%
P/E 507x 88.9x 25.2x 21.4x 18.2x 29x
PBR 1.72x 2.02x 1.99x 1.53x 1.42x 1.35x
PEG - 0x 0x - 1.1x -0.8x
Capitalization / Revenue 0.93x 1.03x 1.03x 0.93x 1x 1.05x
EV / Revenue 1.08x 1.02x 0.84x 0.51x 0.62x 0.84x
EV / EBITDA 11.6x 11.6x 9.9x 4.62x 4.57x 7.76x
EV / EBIT 37.3x 39.5x 33.7x 11.4x 9.78x 23.1x
EV / FCF 21.7x 6.29x 6.2x 2.52x -20.7x -4.81x
FCF Yield 4.6% 15.9% 16.1% 39.7% -4.84% -20.8%
Dividend per Share 2 0.008 0.014 0.1 0.1 0.1 0.055
Rate of return 0.16% 0.23% 1.58% 1.87% 1.9% 1.05%
EPS 2 0.01 0.07 0.25 0.25 0.29 0.18
Distribution rate 80% 20% 40% 40% 34.5% 30.6%
Net sales 1 7,384 8,145 8,809 8,243 7,503 7,075
EBITDA 1 688.6 715.8 747.7 904.6 1,019 767.9
EBIT 1 213.6 210.6 219.6 366.2 476 258.2
Net income 1 12.26 99.03 350.1 358.5 409.8 260.1
Net Debt 1 1,119 -62.17 -1,647 -3,468 -2,876 -1,491
Reference price 2 5.070 6.220 6.310 5.350 5.270 5.220
Nbr of stocks (in thousands) 1,350,702 1,347,873 1,434,316 1,429,103 1,429,103 1,427,088
Announcement Date 3/16/21 3/30/22 3/29/23 3/29/24 4/2/25 4/2/26
1CNY in Million2CNY
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 1.06B
33.76x12.18x24.85x0.59% 1,052B
28.96x - - 2.06% 627B
31.84x7.42x15.42x2.75% 441B
19.79x4.7x11.65x2.81% 349B
21.42x5.54x13.77x2.89% 287B
19.89x4.11x11.68x2.14% 241B
26.26x6.84x12.14x2.43% 224B
13.32x4.79x9.96x3.83% 202B
-42.28x6.13x23.96x2.38% 172B
Average 17.00x 6.46x 15.43x 2.43% 359.62B
Weighted average by Cap. 24.17x 8.04x 17.73x 2%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. 000597 Stock
  4. Valuation Northeast Pharmaceutical Group Co., Ltd.